- Home
- MXCT vs NHS Comparison
MXCT vs NHS Comparison
Compare MXCT & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXCT
- NHS
- Stock Information
- Founded
- MXCT 1999
- NHS 2003
- Country
- MXCT United States
- NHS United States
- Employees
- MXCT N/A
- NHS N/A
- Industry
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- NHS Trusts Except Educational Religious and Charitable
- Sector
- MXCT Health Care
- NHS Finance
- Exchange
- MXCT Nasdaq
- NHS Nasdaq
- Market Cap
- MXCT 275.7M
- NHS 221.6M
- IPO Year
- MXCT 2021
- NHS N/A
- Fundamental
- Price
- MXCT $2.73
- NHS $7.41
- Analyst Decision
- MXCT Strong Buy
- NHS
- Analyst Count
- MXCT 2
- NHS 0
- Target Price
- MXCT $10.00
- NHS N/A
- AVG Volume (30 Days)
- MXCT 621.3K
- NHS 111.8K
- Earning Date
- MXCT 05-07-2025
- NHS 01-01-0001
- Dividend Yield
- MXCT N/A
- NHS 13.44%
- EPS Growth
- MXCT N/A
- NHS N/A
- EPS
- MXCT N/A
- NHS N/A
- Revenue
- MXCT $38,627,000.00
- NHS N/A
- Revenue This Year
- MXCT $9.05
- NHS N/A
- Revenue Next Year
- MXCT $19.98
- NHS N/A
- P/E Ratio
- MXCT N/A
- NHS N/A
- Revenue Growth
- MXCT N/A
- NHS N/A
- 52 Week Low
- MXCT $2.21
- NHS $6.95
- 52 Week High
- MXCT $5.26
- NHS $9.17
- Technical
- Relative Strength Index (RSI)
- MXCT 47.09
- NHS 48.88
- Support Level
- MXCT $2.29
- NHS $7.30
- Resistance Level
- MXCT $2.74
- NHS $7.45
- Average True Range (ATR)
- MXCT 0.24
- NHS 0.21
- MACD
- MXCT 0.06
- NHS 0.03
- Stochastic Oscillator
- MXCT 88.14
- NHS 75.24
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.